OBJ appoints Paul Peros as CEO of new device business, page-264

Bodycare has a chance maybe, being OTC and much lower regulatory barriers; but also remember that is what we were also told about the Cosmetic/Skincare market as well; and that has now taken equally as long as Pharmaceutical clinical trials would have, without any significant revenues to date.

In relation to BodyGuard, I remain extremely cautious as BodyGuard needs successful Phase III clinical trials and somebody to pay for them...and so far in the last decade, no-one has been willing to take that responsibility on. If that responsibility falls on Shareholders, imo you can kiss goodbye to any Shareholder returns for the foreseeable future, as the BodyGuard necessary requirements will easily consume any potential profits from any other successful division for many years.